FindTrial
Sign In

BCMACP03

DRUG2 trials

Sponsors

Galapagos, Galapagos Cell Therapeutics

Conditions

Relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)Relapsed/refractory B-Cell non-Hodgkin lymphomaRelapsed/refractory multiple myelomarelapsed/refractory Multiple Myeloma

Phase 1

A phase I/II open label, multicenter study evaluating the feasibility, safety and efficacy of point-of-care manufactured antiBCMA CAR T cells (GLPG5301; BCMACP03) in subjects with relapsed/refractory Multiple Myeloma (RRMM)
Active, not recruitingCTIS2022-500782-27-00
Galapagosrelapsed/refractory Multiple Myeloma
Start: 2023-11-14Target: 41Updated: 2026-01-22

Phase 3

A long-term follow-up study for patients treated with Galapagos CAR T-cell therapies
RecruitingCTIS2023-510173-34-00
Galapagos Cell TherapeuticsRelapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Relapsed/refractory B-Cell non-Hodgkin lymphoma, Relapsed/refractory multiple myeloma
Start: 2024-07-26Target: 177Updated: 2025-11-28

Related Papers

Rationale for and Design of Papilio-1: A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Feasibility, Safety, and Efficacy of Point-of-Care-Manufactured Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells (GLPG5301) in Relapsed/Refractory Multiple Myeloma
Blood2023-11-021 citations